At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 16 enrolled
Drug / intervention
CVA21 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Study to Evaluate the Safety and Clinical Activity of Intravesicular CAVATAK (Coxsackievirus A21, CVA21) Alone and in Sequential Combination With Low Dose Mitomycin C in Patients With Non-Muscle Invasive Bladder Cancer (VLA-012 CANON)
In Brief
A Phase 1 clinical trial evaluating CVA21 and Mitomycin C for Non-muscle Invasive Bladder Cancer. Completed, enrolled 16 participants across 1 site.
Detailed Summary
The study consisted of 2 sequential parts. Part A assessed the safety and tolerability of CAVATAK administered via intravesical instillation in patients with non-muscle invasive bladder cancer scheduled to undergo TUR. Part B assessed the safety and tolerability of CAVATAK administered in sequential combination with low dose Mitomycin C in the same patient population.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-muscle Invasive Bladder Cancer
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 2014
Enrollment StartJan 2015
Primary CompletionMar 2016
TodayJul 2026
First PostedDec 12, 2014
Enrollment StartJan 16, 2015
Primary CompletionMar 14, 2016
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 11.6 years ago
Interventions
CVA21biological
CAVATAK is a purified preparation of CVA21
Mitomycin Cdrug
Chemotherapy